{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:40:04Z","timestamp":1792582804790,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"DOI":"10.1038\/s41409-026-02949-3","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:51:39Z","timestamp":1792579899000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Allogeneic transplantation for plasma cell myeloma clears pre-transplant clonal haematopoiesis and is associated with a low rate of myeloid neoplasm post-cytotoxic-therapy"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8653-4844","authenticated-orcid":false,"given":"Michael","family":"Ashby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Anstee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7417-4343","authenticated-orcid":false,"given":"Ing S.","family":"Tiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun","family":"Loo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0531-7424","authenticated-orcid":false,"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7514-3298","authenticated-orcid":false,"given":"Andrew H.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"2949_CR1","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc.2017.60","volume":"17","author":"ME McNerney","year":"2017","unstructured":"McNerney ME, Godley LA, Le Beau MM. Therapy-related myeloid neoplasms: when genetics and environment collide. Nat Rev Cancer. 2017;17:513\u201327.","journal-title":"Nat Rev Cancer"},{"key":"2949_CR2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","volume":"18","author":"K Takahashi","year":"2017","unstructured":"Takahashi K, Wang F, Kantarjian H, Doss D, Khanna K, Thompson E, et al. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol. 2017;18:100\u201311.","journal-title":"Lancet Oncol"},{"key":"2949_CR3","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327:464\u201377.","journal-title":"JAMA"},{"key":"2949_CR4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398:314\u201324.","journal-title":"Lancet"},{"key":"2949_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.clml.2014.07.001","volume":"15","author":"N Pemmaraju","year":"2015","unstructured":"Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras Gonz\u00e1lez GM, Baladandayuthapani V, et al. Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015;15:110\u20134.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2949_CR6","doi-asserted-by":"publisher","first-page":"4086","DOI":"10.1182\/blood-2011-05-355743","volume":"118","author":"S Mailankody","year":"2011","unstructured":"Mailankody S, Pfeiffer RM, Kristinsson SY, Korde N, Bjorkholm M, Goldin LR, et al. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood. 2011;118:4086\u201392.","journal-title":"Blood"},{"key":"2949_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1034\/j.1600-0609.2000.90218.x","volume":"65","author":"FL Group","year":"2000","unstructured":"Group FL. Acute leukaemia and other secondary neoplasms in patients treated with conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study. Eur J Haematol. 2000;65:123\u20137.","journal-title":"Eur J Haematol"},{"key":"2949_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16805-5","volume":"11","author":"TH Mouhieddine","year":"2020","unstructured":"Mouhieddine TH, Sperling AS, Redd R, Park J, Leventhal M, Gibson CJ, et al. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020;11:2996.","journal-title":"Nat Commun"},{"key":"2949_CR9","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1182\/bloodadvances.2019001157","volume":"4","author":"JF Soerensen","year":"2020","unstructured":"Soerensen JF, Aggerholm A, Kerndrup GB, Hansen MC, Ewald IKL, Bill M, et al. Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post\u2013autologous stem cell transplantation. Blood Adv. 2020;4:885\u201392.","journal-title":"Blood Adv"},{"key":"2949_CR10","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.3324\/haematol.2012.064121","volume":"97","author":"S Matarraz","year":"2012","unstructured":"Matarraz S, Paiva B, Diez-Campelo M, L\u00f3pez-Corral L, P\u00e9rez E, Mateos MV, et al. Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide? Haematologica. 2012;97:1608\u201311.","journal-title":"Haematologica"},{"key":"2949_CR11","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s00277-021-04514-y","volume":"100","author":"S Luoma","year":"2021","unstructured":"Luoma S, Silvennoinen R, Rauhala A, Niittyvuopio R, Martelin E, Lindstr\u00f6m V, et al. Long-term outcome after allogeneic stem cell transplantation in multiple myeloma. Ann Hematol. 2021;100:1553\u201367.","journal-title":"Ann Hematol"},{"key":"2949_CR12","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","volume":"371","author":"S Jaiswal","year":"2014","unstructured":"Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488\u201398.","journal-title":"N Engl J Med"},{"key":"2949_CR13","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1182\/bloodadvances.2025016374","volume":"9","author":"CH Kok","year":"2025","unstructured":"Kok CH, Al-Kali A, Thomas D, He R, Kutyna MM, Alkhateeb H, et al. RAS mutation identifies a poor prognostic molecular subtype of therapy-related myeloid neoplasm. Blood Adv. 2025;9:3814\u20138.","journal-title":"Blood Adv"},{"key":"2949_CR14","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1038\/s41375-025-02605-7","volume":"39","author":"N Gazeau","year":"2025","unstructured":"Gazeau N, Beauvais D, Tilmont R, Srour M, Ferrant E, Safar V, et al. Myeloid neoplasms after CD19-directed CAR T cells therapy in long-term B-cell lymphoma responders, a rising risk over time? Leukemia. 2025;39:1714\u201322.","journal-title":"Leukemia"},{"key":"2949_CR15","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1182\/bloodadvances.2025015981","volume":"9","author":"JN Gustine","year":"2025","unstructured":"Gustine JN, Branagan AR, Cirstea DD, Rexha F, Han R, Yee AJ, et al. Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myeloma. Blood Adv. 2025;9:3026\u201330.","journal-title":"Blood Adv"},{"key":"2949_CR16","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1182\/blood.2020010483","volume":"138","author":"T Tanaka","year":"2021","unstructured":"Tanaka T, Morita K, Loghavi S, Wang F, Furudate K, Sasaki Y, et al. Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia. Blood. 2021;138:1733\u20139.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02949-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02949-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02949-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:51:40Z","timestamp":1792579900000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02949-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":16,"alternative-id":["2949"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02949-3","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}